Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VA692 is a small molecule selective cyclooxygenase-2 (COX-2) inhibitor belonging to the vicinal diaryl-substituted heterocyclic chemical class. It has been investigated for its potential antitumor properties, specifically its ability to inhibit the growth of cancer cell lines such as HT-29 colorectal carcinoma and MDA-MB-231 breast carcinoma. In comparative studies, VA692 demonstrated growth-inhibitory activity, although it was found to be less potent than its analog VA1213. The compound's mechanism of action involves the inhibition of the COX-2 enzyme, which is frequently overexpressed in various cancers and contributes to tumor progression and survival.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VA692.